Refining Combination Strategies in Metastatic RCC

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.

Drs Toni Choueiri and Robert J. Motzer discuss factors that impact their decisions for treatment of metastatic renal cell carcinoma in the first-line setting and highlight their go-to regimens.

Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.

Treatment-related adverse events to be mindful of when treating patients with metastatic renal cell carcinoma with a TKI/IO regimen, such as lenvatinib and pembrolizumab, in the frontline setting.

Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.

Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.

This article reviews the results of the phase 3 KEYNOTE-581/CLEAR trial and features expert insights from trial investigators, Robert J. Motzer, MD, and Toni Choueiri, MD.